View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jørgen Lian
  • Jørgen Lian

Scorpio Tankers (Buy, TP: USD92.00) - Set to pivot from debt to distri...

We see ongoing support for the product tanker markets from geopolitics and a fundamentally strong supply and demand outlook even though the orderbook is creeping up. We would expect Scorpio Tankers to redirect cash flows to shareholder returns when it hits its debt target. We estimate current rates leave more than USD4/share in quarterly firepower (23% yield), with the stock now trading at a P/NAV of 0.9x. We reiterate our BUY, and have raised our target price to USD92 (83).

 PRESS RELEASE

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent ...

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights BOSTON, May 09, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first quarter 2024. Recent Business Highlights CUE-101 abstract accepted for an oral presentation and poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 31-June 4, 2024.C...

 PRESS RELEASE

Olema Oncology Reports First Quarter 2024 Financial Results and Provid...

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will host an investor conference call on May 15, 2024, at 8:00 a.m. ET to review the dataInvestigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, expected to be filed with FDA in late 2024Cash, cas...

 PRESS RELEASE

Keros Therapeutics Reports Recent Business Highlights and First Quarte...

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remain...

 PRESS RELEASE

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit BOSTON, May 08, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the , the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually. Presentation Details Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDTSession: Po...

 PRESS RELEASE

Olema Oncology Announces New Clinical Data for Palazestrant in Combina...

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024 SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --  (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will present new clinical data from the Company’s ongoing Phase 1b/2 clinical study of palazestrant...

 PRESS RELEASE

SFL - Invitation to Presentation of Q1 2024 Results

SFL - Invitation to Presentation of Q1 2024 Results SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at  In order to listen to the conference call and presentation, you may do one of the following: A: Join Confere...

 PRESS RELEASE

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life...

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference BOSTON, May 07, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024. During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress. Presentation Details The Citizens J...

 PRESS RELEASE

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conf...

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference ...

Wedbush Research
  • Wedbush Research
TPX TEMPUR SEALY INTERNATIONAL INC
GEO GEO GROUP INC. (THE)
2454 MEDIATEK INC.
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
QRVO QORVO INC.
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
VRNS VARONIS SYSTEMS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
MGPI MGP INGREDIENTS INC.
MFA MFA FINANCIAL INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
FHN FIRST HORIZON CORPORATION
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CNK CINEMARK HOLDINGS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
OSTK OVERSTOCK.COM INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CELH CELSIUS HOLDINGS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
AVGO BROADCOM INC.
TENB TENABLE HOLDINGS
GOSS GOSSAMER BIO
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ORIC INC.
TVTX ORIC PHARMACEUTICALS
PLTR TRAVERE THERAPEUTICS INC
DAWN PALANTIR TECHNOLOGIES
TDUP DAY ONE BIOPHARMACEUTICALS INC
MRVL THREDUP INC.
STX MARVELL TECHNOLOGY INC
HOWL SEAGATE TECHNOLOGY HLDGS PLC
PAY WEREWOLF THERAPEUTICS INC
GFS PAYMENTUS HLDGS INC
BROS GLOBALFOUNDRIES INC
DUTCH BROS INC

Sarepta Therapeutics Inc: 1 director

A director at Sarepta Therapeutics Inc sold 3,635 shares at 140.000USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 4, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 2, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch